S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
U.S. Loses to China in Shocking WAR GAMES (Ad)
Slow start to New York's legal pot market leaves farmers holding the bag
With oil prices slumping, OPEC+ producers weigh more production cuts
U.S. Loses to China in Shocking WAR GAMES (Ad)
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
Apple is expected to unveil a sleek, pricey headset. Is it the device VR has been looking for?
We Called (ARWR) In Advance, Which Stocks Are Next? (Ad)
Chuck Todd says he's leaving 'Meet the Press' after a tumultuous near-decade moderating the NBC political panel show
Oil tanker breaks down in Egypt's Suez Canal, briefly disrupting traffic in the global waterway
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
U.S. Loses to China in Shocking WAR GAMES (Ad)
Slow start to New York's legal pot market leaves farmers holding the bag
With oil prices slumping, OPEC+ producers weigh more production cuts
U.S. Loses to China in Shocking WAR GAMES (Ad)
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
Apple is expected to unveil a sleek, pricey headset. Is it the device VR has been looking for?
We Called (ARWR) In Advance, Which Stocks Are Next? (Ad)
Chuck Todd says he's leaving 'Meet the Press' after a tumultuous near-decade moderating the NBC political panel show
Oil tanker breaks down in Egypt's Suez Canal, briefly disrupting traffic in the global waterway
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
U.S. Loses to China in Shocking WAR GAMES (Ad)
Slow start to New York's legal pot market leaves farmers holding the bag
With oil prices slumping, OPEC+ producers weigh more production cuts
U.S. Loses to China in Shocking WAR GAMES (Ad)
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
Apple is expected to unveil a sleek, pricey headset. Is it the device VR has been looking for?
We Called (ARWR) In Advance, Which Stocks Are Next? (Ad)
Chuck Todd says he's leaving 'Meet the Press' after a tumultuous near-decade moderating the NBC political panel show
Oil tanker breaks down in Egypt's Suez Canal, briefly disrupting traffic in the global waterway
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
U.S. Loses to China in Shocking WAR GAMES (Ad)
Slow start to New York's legal pot market leaves farmers holding the bag
With oil prices slumping, OPEC+ producers weigh more production cuts
U.S. Loses to China in Shocking WAR GAMES (Ad)
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
Apple is expected to unveil a sleek, pricey headset. Is it the device VR has been looking for?
We Called (ARWR) In Advance, Which Stocks Are Next? (Ad)
Chuck Todd says he's leaving 'Meet the Press' after a tumultuous near-decade moderating the NBC political panel show
Oil tanker breaks down in Egypt's Suez Canal, briefly disrupting traffic in the global waterway
NASDAQ:ORIC

ORIC Pharmaceuticals (ORIC) Stock Forecast, Price & News

$5.32
+0.05 (+0.95%)
(As of 06/2/2023 ET)
Compare
Today's Range
$5.28
$5.43
50-Day Range
$4.73
$6.15
52-Week Range
$2.36
$6.85
Volume
149,953 shs
Average Volume
95,804 shs
Market Capitalization
$239.88 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$13.20

ORIC Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
148.1% Upside
$13.20 Price Target
Short Interest
Bearish
13.67% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.58
Upright™ Environmental Score
News Sentiment
1.10mentions of ORIC Pharmaceuticals in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($2.20) to ($2.02) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.40 out of 5 stars

Medical Sector

173rd out of 983 stocks

Pharmaceutical Preparations Industry

73rd out of 486 stocks


ORIC stock logo

About ORIC Pharmaceuticals (NASDAQ:ORIC) Stock

ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer; and ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations. The company is also developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms. It has a license and collaboration agreement with Voronoi Inc.; and a license agreement with Mirati Therapeutics, Inc. The company was incorporated in 2014 and is headquartered in South San Francisco, California.

Receive ORIC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ORIC Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ORIC Stock News Headlines

We Called (ARWR) In Advance, Which Stocks Are Next?
Nearly 56% gains in 30 days! This bullish trend reversal was not only forecasted by A.I., but we called it 1 – 3 days in advance. If you have any money invested in the markets…even just your retirement, you’ll want to see this. Plus, it’s FREE - the training is only an hour & LIVE.
We Called (ARWR) In Advance, Which Stocks Are Next?
Nearly 56% gains in 30 days! This bullish trend reversal was not only forecasted by A.I., but we called it 1 – 3 days in advance. If you have any money invested in the markets…even just your retirement, you’ll want to see this. Plus, it’s FREE - the training is only an hour & LIVE.
4 Analysts Have This to Say About ORIC Pharmaceuticals
See More Headlines

ORIC Price History

ORIC Company Calendar

Last Earnings
3/16/2023
Today
6/03/2023
Next Earnings (Estimated)
8/10/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ORIC
Fax
N/A
Employees
78
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$13.20
High Stock Price Forecast
$15.00
Low Stock Price Forecast
$8.00
Forecasted Upside/Downside
+148.1%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
5 Analysts

Profitability

Net Income
$-89,120,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$4.50 per share

Miscellaneous

Free Float
42,685,000
Market Cap
$239.88 million
Optionable
Not Optionable
Beta
0.49

Key Executives

  • Dr. Richard A. Heyman Ph.D. (Age 65)
    Co-Founder, Independent Chairman & Member of Scientific Advisory Board
    Comp: $89.92k
  • Dr. Jacob M. Chacko M.B.A. (Age 43)
    M.D., Pres, CEO & Director
    Comp: $883.68k
  • Mr. Dominic G. Piscitelli CPA (Age 47)
    CPA, M.B.A., Chief Financial Officer
    Comp: $610.02k
  • Dr. Pratik S. Multani M.D. (Age 55)
    M.S., Chief Medical Officer
    Comp: $669.76k
  • Dr. Charles L. Sawyers B.A. (Age 63)
    BA, M.D., Ph.D., Co-Founder & Member of Scientific Advisory Board
  • Dr. Scott W. Lowe Ph.D.
    Co-Founder & Member of Scientific Advisory Board
  • Dr. Lori Sickels Friedman Ph.D. (Age 58)
    Chief Scientific Officer
  • Dr. Christian V. Kuhlen Esq. (Age 49)
    J.D., M.D., Gen. Counsel
  • Mr. Daniel Iazzetti
    VP & Head of People
  • Dr. Edna Chow Maneval (Age 62)
    Sr. VP of Clinical Devel.













ORIC Stock - Frequently Asked Questions

Should I buy or sell ORIC Pharmaceuticals stock right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ORIC Pharmaceuticals in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ORIC shares.
View ORIC analyst ratings
or view top-rated stocks.

What is ORIC Pharmaceuticals' stock price forecast for 2023?

5 equities research analysts have issued 12 month target prices for ORIC Pharmaceuticals' shares. Their ORIC share price forecasts range from $8.00 to $15.00. On average, they expect the company's stock price to reach $13.20 in the next year. This suggests a possible upside of 148.1% from the stock's current price.
View analysts price targets for ORIC
or view top-rated stocks among Wall Street analysts.

How have ORIC shares performed in 2023?

ORIC Pharmaceuticals' stock was trading at $5.89 on January 1st, 2023. Since then, ORIC shares have decreased by 9.7% and is now trading at $5.32.
View the best growth stocks for 2023 here
.

When is ORIC Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 10th 2023.
View our ORIC earnings forecast
.

How were ORIC Pharmaceuticals' earnings last quarter?

ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) announced its earnings results on Thursday, March, 16th. The company reported ($0.52) earnings per share for the quarter, topping the consensus estimate of ($0.56) by $0.04.

What other stocks do shareholders of ORIC Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ORIC Pharmaceuticals investors own include Pfizer (PFE), Intel (INTC), CrowdStrike (CRWD), Valero Energy (VLO), Hello Group (MOMO), ONEOK (OKE), DocuSign (DOCU), Vaxart (VXRT), Delta Air Lines (DAL) and Datadog (DDOG).

When did ORIC Pharmaceuticals IPO?

(ORIC) raised $75 million in an IPO on Friday, April 24th 2020. The company issued 5,000,000 shares at $14.00-$16.00 per share. J.P. Morgan, Citigroup, Jefferies and Guggenheim Securities served as the underwriters for the IPO.

What is ORIC Pharmaceuticals' stock symbol?

ORIC Pharmaceuticals trades on the NASDAQ under the ticker symbol "ORIC."

Who are ORIC Pharmaceuticals' major shareholders?

ORIC Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional shareholders include FMR LLC (8.89%), Prosight Management LP (3.43%), BlackRock Inc. (1.53%), Renaissance Technologies LLC (0.76%), Geode Capital Management LLC (0.68%) and ArrowMark Colorado Holdings LLC (0.57%). Insiders that own company stock include Carl L Gordon, Dominic Piscitelli, Jacob Chacko, Orbimed Advisors Llc, Pratik S Multani, Richard A Heyman, Richard A Heyman and Richard H Scheller.
View institutional ownership trends
.

How do I buy shares of ORIC Pharmaceuticals?

Shares of ORIC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is ORIC Pharmaceuticals' stock price today?

One share of ORIC stock can currently be purchased for approximately $5.32.

How much money does ORIC Pharmaceuticals make?

ORIC Pharmaceuticals (NASDAQ:ORIC) has a market capitalization of $239.88 million. The company earns $-89,120,000.00 in net income (profit) each year or ($2.19) on an earnings per share basis.

How can I contact ORIC Pharmaceuticals?

ORIC Pharmaceuticals' mailing address is 240 E. GRAND AVE. 2ND FLOOR, SOUTH SAN FRANCISCO CA, 94080. The official website for the company is www.oricpharma.com. The company can be reached via phone at 650-388-5600 or via email at investors@oricpharma.com.

This page (NASDAQ:ORIC) was last updated on 6/4/2023 by MarketBeat.com Staff

My Account -